Immunocore Holdings Management
Management criteria checks 3/4
Immunocore Holdings' CEO is Bahija Jallal, appointed in Jan 2019, has a tenure of 7.25 years. total yearly compensation is $10.89M, comprised of 7% salary and 93% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $388.35K. The average tenure of the management team and the board of directors is 3.2 years and 5.4 years respectively.
Key information
Bahija Jallal
Chief executive officer
US$10.9m
Total compensation
| CEO salary percentage | 7.03% |
| CEO tenure | 7.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 3.2yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst
Nov 08Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?
Aug 02
Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Jun 10Immunocore Holdings: A Name On My Watch List
Apr 27Improved Revenues Required Before Immunocore Holdings plc (NASDAQ:IMCR) Shares Find Their Feet
Apr 26
AI Tools And Global Expansion Will Broaden KIMMTRAK's Market Reach
Expansion into less dense U.S. markets and international launches are key to driving revenue growth for Immunocore's KIMMTRAK.Is Immunocore Holdings (NASDAQ:IMCR) Using Too Much Debt?
Mar 04Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point
Feb 27There Is A Reason Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Undemanding
Jan 08Immunocore Is Adequately Valued, But Its Prospects Are Uncertain
Dec 10Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Oct 24Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry
Sep 19Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Aug 12Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?
Jul 24Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Jun 16Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
May 11Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 11Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Apr 05Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
Jan 22Immunocore Holdings: Vulnerable To Profit Taking After Big Rally
Jan 21Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%
Dec 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$11m | US$765k | -US$36m |
| Sep 30 2025 | n/a | n/a | -US$29m |
| Jun 30 2025 | n/a | n/a | -US$20m |
| Mar 31 2025 | n/a | n/a | -US$22m |
| Dec 31 2024 | US$13m | US$760k | -US$51m |
| Sep 30 2024 | n/a | n/a | -US$47m |
| Jun 30 2024 | n/a | n/a | -US$55m |
| Mar 31 2024 | n/a | n/a | -US$60m |
| Dec 31 2023 | US$12m | US$735k | -US$55m |
| Sep 30 2023 | n/a | n/a | -US$69m |
| Jun 30 2023 | n/a | n/a | -US$61m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$1m | US$700k | -US$53m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$112m |
| Mar 31 2022 | n/a | n/a | -US$156m |
| Dec 31 2021 | US$35m | US$700k | -US$180m |
| Sep 30 2021 | n/a | n/a | -US$150m |
| Jun 30 2021 | n/a | n/a | -US$139m |
| Mar 31 2021 | n/a | n/a | -US$116m |
| Dec 31 2020 | US$1m | n/a | -US$101m |
Compensation vs Market: Bahija's total compensation ($USD10.89M) is above average for companies of similar size in the US market ($USD5.28M).
Compensation vs Earnings: Bahija's compensation has been consistent with company performance over the past year.
CEO
Bahija Jallal (64 yo)
Dr. Bahija Jallal, Ph.D. served as Director of Outpace Bio, Inc. She serves as Chief Executive Officer and Director of Immunocore Holdings plc (formerly known as Immunocore Holdings Limited) since January...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 7.3yrs | US$10.89m | 0.024% $ 365.4k | |
| CFO, Executive VP & Head of Corporate Development | 1.3yrs | US$5.17m | no data | |
| Executive VP & Chief Human Resources Officer | 4.2yrs | US$1.21m | 0.0022% $ 33.2k | |
| SVP & Chief Operating Officer | 2.3yrs | no data | no data | |
| SVP, Finance & Chief Accounting Officer | 2.3yrs | no data | 0.0013% $ 19.4k | |
| Senior VP | no data | no data | no data | |
| VP & Chief Information Officer | 2.3yrs | no data | no data | |
| Executive VP | 5.3yrs | no data | no data | |
| Chief Compliance Officer | 2.3yrs | no data | no data | |
| Vice President of Communications | 4.3yrs | no data | no data | |
| VP & Chief of Staff | 4.3yrs | no data | no data | |
| Senior Vice President of Research | no data | no data | no data |
Experienced Management: IMCR's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 7.3yrs | US$10.89m | 0.024% $ 365.4k | |
| Independent Non-Executive Chairman | 11.1yrs | US$498.94k | 0.027% $ 398.2k | |
| Independent Non-Executive Director | 8.4yrs | US$472.53k | 0% $ 0 | |
| Independent Non-Executive Director | 5.3yrs | US$471.42k | 0% $ 0 | |
| Independent Non-Executive Director | 5.4yrs | US$464.99k | 0.00066% $ 9.9k | |
| Independent Non-Executive Director | 1.2yrs | US$842.45k | 0% $ 0 | |
| Independent Non-Executive Director | 3.8yrs | US$477.49k | 0% $ 0 |
Experienced Board: IMCR's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/22 21:44 |
| End of Day Share Price | 2026/04/22 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immunocore Holdings plc is covered by 27 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |